EGFR and lung adenocarcinoma: A more recent study by Cheng et al. retrospectively analyzed 78 patients with EGFR-mutant lung adenocarcinoma who developed BMs and received either a combination of EGFR-TKIs and RT (WBRT or SRS) or EGFR-TKI alone.